Cascade Chemistry, a contract improvement and manufacturing group (CDMO) serving the pharmaceutical business, will produce the lively pharmaceutical ingredient (API) for RBT-9 on behalf of consumer Renibus Therapeutics. The investigational remedy is coming into a Phase II trial for COVID-19 sufferers at excessive threat due to age or comorbid circumstances (reminiscent of kidney or heart problems).
RBT-9 is being developed by Renibus Therapeutics as an antiviral remedy with organ-protective attributes. The drug, not too long ago awarded quick monitor designation by the US Food and Drug Administration (FDA) reportedly has demonstrated antiviral properties in addition to immune-modulating actions in preclinical research.
At the onset of the COVID-19 pandemic, Renibus Therapeutics reportedly labored rapidly to plan and provoke an RVT-9 trial for COVID-19 sufferers. According to Cascade Chemistry, Renibus selected its manufacturing companion based mostly on expertise, flexibility and repair focus.
Alvaro Guillem, CEO of Renibus Therapeutics, mentioned Cascade Chemistry supplied the data and capabilities mandatory to orchestrate and implement an efficient technique.
“Cascade’s ability to move quickly to design, implement, and scale-up a comprehensive RBT-9 API manufacturing strategy has been one of the essential elements in our campaign to initiate clinical trials with minimal delay,” Guillem mentioned. “The professionalism, experience, flexibility, and consumer dedication of the Cascade crew have facilitated our collaborative effort to advance efficient therapies for this devastating international pandemic.”